Gossamer Bio (GOSS) began trading on the Nasdaq on 8 February 2019

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

Sector: Healthcare

• Industry: Biotechnology
• Full Time Employees: 144
• Founded by Faheem Hasnain and Sheila Gujrathi in 2015
• Headquartered in San Diego, California
• https://www.gossamerbio.com

Ticker: GOSS

Gossamer Bio opened for trading at $19 after pricing upsized 17.25 mln share IPO (from 14.375 mln shares) IPO at $16, in-line with expected range